We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A Multicenter, Prospective, Observational Study to Evaluate Ethanol-Induced Symptoms in Patients Receiving Docetaxel Chemotherapy.
- Authors
Young-Woong Won; Jin-Hyoung Kang; Jung Hye Kwon; Dong-Hoe Koo; Jung Hun Kang; Chi Hoon Maeng; Hee Kyung Ahn; Sung Yong Oh; Dae-Won Lee; Joohyuk Sohn; So Yeon Oh; Kyung Hee Lee; Su-Jin Koh; Keun Seok Lee; Chan-Kyu Kim; Ji-Yeon Kim; Jun Ho Ji; Sung-Bae Kim; Joo Young Ha; Ho Young Kim
- Abstract
Purpose Several previous studies and case reports have reported ethanol-induced symptoms in patients receiving anticancer drugs containing ethanol. Most docetaxel formulations contain ethanol as a solvent. However, there are insufficient data on ethanol-induced symptoms when docetaxel-containing ethanol is administered. The primary purpose of this study was to investigate the frequency and pattern of ethanol-induced symptoms during and after docetaxel administration. The secondary purpose was to explore the risk factors for ethanol-induced symptoms. Materials and Methods This was a prospective, multicenter, observational study. The participants filled out ethanol-induced symptom questionnaire on the day of chemotherapy and the following day. Results Data from 451 patients were analyzed. The overall occurrence rate of ethanol-induced symptoms was 44.3% (200/451 patients). The occurrence rate of facial flushing was highest at 19.7% (89/451 patients), followed by nausea in 18.2% (82/451 patients), and dizziness in 17.5% (79/451 patients). Although infrequent, unsteady walking and impaired balance occurred in 4.2% and 3.3% of patients, respectively. Female sex, presence of underlying disease, younger age, docetaxel dose, and docetaxel-containing ethanol amount were significantly associated with the occurrence of ethanol-induced symptoms. Conclusion The occurrence of ethanol-induced symptoms was not low in patients receiving docetaxel-containing ethanol. Physicians need to pay more attention to the occurrence of ethanol-induced symptoms and prescribe ethanol-free or low-ethanol-containing formulations to high-risk patients.
- Subjects
DOCETAXEL; SCIENTIFIC observation; CANCER chemotherapy; ANTINEOPLASTIC agents; SYMPTOMS
- Publication
Cancer Research & Treatment, 2023, Vol 55, Issue 4, p1096
- ISSN
1598-2998
- Publication type
Article
- DOI
10.4143/crt.2022.1565